Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 16;15(5):8773–8794. doi: 10.3390/ijms15058773

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 by the authors; licensee MDPI, Basel, Switzerland

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

PMC Copyright notice

Figure 3. — Multicellular spheroid growth of H1_DL2 cells after treatment with vemurafenib and temsirolimus. (A, left) Spheroid diameters measured zero and eight days after treatment with 10 μM of temsirolimus, 10 μM of vemurafenib or the combined treatment (5 μM temsirolimus + 5 μM vemurafenib) (n = 6, mean ± SD). n.s.: not significant; * p < 0.05, **** p < 0.0001. (A, right) The percentage of dead cells within the spheroids after treatment for three days with 10 μM of temsirolimus, 10 μM of vemurafenib or the combined treatment (5 μM temsirolimus + 5 μM vemurafenib); (B) Maximum intensity projection images of the red channel (dead cells) of confocal image stacks of spheroids treated with 10 μM of temsirolimus, 10 μM of vemurafenib or the combined treatment (5 μM temsirolimus + 5 μM vemurafenib); (C) The surface volume of the green channel (live cells) of the same spheroids as in (B); and (D) An overlay of the red and green volume surfaces of the same spheroids as in (B). Scale bar = 100 μm. neg. control = negative control.